NO964073L - Diagnose og terapi samt cellulære og dyremodeller for sykdommer assosiert med mitokondriske defekter - Google Patents

Diagnose og terapi samt cellulære og dyremodeller for sykdommer assosiert med mitokondriske defekter

Info

Publication number
NO964073L
NO964073L NO964073A NO964073A NO964073L NO 964073 L NO964073 L NO 964073L NO 964073 A NO964073 A NO 964073A NO 964073 A NO964073 A NO 964073A NO 964073 L NO964073 L NO 964073L
Authority
NO
Norway
Prior art keywords
disease
mitochondrial
methods
therapy
mitochondria
Prior art date
Application number
NO964073A
Other languages
English (en)
Norwegian (no)
Other versions
NO964073D0 (no
Inventor
Corinna Herrnstadt
William Davis Parker
Robert E Davis
Scott Wiliam Miller
Original Assignee
Mitokor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/219,842 external-priority patent/US5565323A/en
Priority claimed from US08/397,808 external-priority patent/US5888498A/en
Application filed by Mitokor filed Critical Mitokor
Publication of NO964073D0 publication Critical patent/NO964073D0/no
Publication of NO964073L publication Critical patent/NO964073L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0053—Oxidoreductases (1.) acting on a heme group of donors (1.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
NO964073A 1994-03-30 1996-09-27 Diagnose og terapi samt cellulære og dyremodeller for sykdommer assosiert med mitokondriske defekter NO964073L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/219,842 US5565323A (en) 1994-03-30 1994-03-30 Cytochrome oxidase mutations aiding diagnosis of sporadic alzheimer's disease
US08/397,808 US5888498A (en) 1995-03-03 1995-03-03 Cellular and animal models for diseases associated with mitochondrial defects
PCT/US1995/004063 WO1995026973A1 (en) 1994-03-30 1995-03-30 Diagnosis, therapy and cellular and animal models for diseases associated with mitochondrial defects

Publications (2)

Publication Number Publication Date
NO964073D0 NO964073D0 (no) 1996-09-27
NO964073L true NO964073L (no) 1996-11-29

Family

ID=26914309

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964073A NO964073L (no) 1994-03-30 1996-09-27 Diagnose og terapi samt cellulære og dyremodeller for sykdommer assosiert med mitokondriske defekter

Country Status (12)

Country Link
US (1) US20010021526A1 (ja)
EP (1) EP0751951A4 (ja)
JP (1) JPH09511398A (ja)
CN (1) CN1150433A (ja)
AU (1) AU705230B2 (ja)
BR (1) BR9507241A (ja)
CA (1) CA2186636A1 (ja)
FI (1) FI963884A7 (ja)
MX (1) MX9604400A (ja)
NO (1) NO964073L (ja)
NZ (1) NZ283660A (ja)
WO (1) WO1995026973A1 (ja)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115364B1 (en) 1993-10-26 2006-10-03 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6027880A (en) 1995-08-02 2000-02-22 Affymetrix, Inc. Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
US20060229824A1 (en) 1993-10-26 2006-10-12 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes
US5840493A (en) * 1994-03-30 1998-11-24 Mitokor Mitochondrial DNA mutations that segregate with late onset diabetes mellitus
US6291172B1 (en) 1995-03-03 2001-09-18 Mitokor Diagnostic assay for diabetes mellitus based on mutational burden
AU5296496A (en) * 1995-03-24 1996-10-16 Mitokor Mutation detection by differential primer extension of mutant and wildtype target sequences
US6391550B1 (en) 1996-09-19 2002-05-21 Affymetrix, Inc. Identification of molecular sequence signatures and methods involving the same
GB9620028D0 (en) 1996-09-26 1996-11-13 Ludwig Inst Cancer Res Factors which interact with oncoproteins
AU3872399A (en) * 1998-04-28 1999-11-16 Mitokor Cellular and animal models for diseases associated with altered mitochondrial function
US6441149B1 (en) 1998-06-15 2002-08-27 Mitokor Diagnostic method based on quantification of extramitochondrial DNA
US6489095B2 (en) 1998-06-15 2002-12-03 Mitokor Diagnostic method based on quantification of extramitochondrial DNA
EP1808177B1 (en) * 1999-02-23 2018-08-08 The Regents of The University of California Methods of treatment of mitochondrial disorders
EP1161534A1 (en) * 1999-03-16 2001-12-12 Mitokor Differential expression of organellar gene products
WO2001020977A1 (fr) * 1999-09-17 2001-03-29 Aventis Pharma S.A. Nouveau modele animal de la maladie d'alzheimer presentant a la fois des plaques amyloides et des dysfonctionnements mitochondriaux
FR2798556B1 (fr) * 1999-09-17 2004-02-27 Aventis Pharma Sa Nouveau modele animal de la maladie d'alzheimer presentant a la fois des plaques amyloides et des dysfonctionnements mitochondriaux
CN1277995A (zh) * 1999-11-22 2000-12-27 上海博容基因开发有限公司 一种新的多肽——人细胞色素氧化酶相关蛋白37和编码这种多肽的多核苷酸
EP1229130B1 (en) * 2000-12-04 2013-11-20 Primagen B.V. Tests based on nucleic acids of endosymbiont cellular organelles
JP2003116576A (ja) * 2001-10-17 2003-04-22 Gifu International Institute Of Biotechnology ヒトミトコンドリアｄｎａを用いた遺伝子検出方法
US7888334B2 (en) 2003-08-22 2011-02-15 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
CN1839142B (zh) 2003-08-22 2010-06-16 澳新制药公司 用作靶向线粒体的抗氧化剂的线粒体醌衍生物
CA2599709A1 (en) 2005-03-09 2006-09-21 Cepheid Polar dyes
EP2641617A1 (en) 2007-05-02 2013-09-25 THE McLEAN HOSPITAL CORPORATION Methods and compositions for mitochondrial replacement therapy
IL282198B2 (en) 2011-09-11 2025-11-01 Minovia Therapeutics Ltd Compositions of functional mitochondria and uses thereof
KR20150063557A (ko) * 2012-10-05 2015-06-09 뉴로바이브 파마슈티컬 에이비 미토콘드리아 독성 테스트
KR101556439B1 (ko) 2013-07-01 2015-10-15 서울대학교산학협력단 미토콘드리아 역행성 신호 경로와 관련된 ＲＸＲα의 기능 및 용도
ES3052812T3 (en) 2017-05-08 2026-01-14 Flagship Pioneering Innovations V Inc Compositions for facilitating membrane fusion and uses thereof
CN107746889A (zh) * 2017-07-17 2018-03-02 国家海洋局北海环境监测中心 用于扩增底栖多毛类环节动物线粒体co i基因片段的引物
JP7454548B2 (ja) 2018-07-22 2024-03-22 ミノヴィア セラピューティクス リミテッド 膵臓疾患のミトコンドリア増強療法
IL280163B2 (en) 2018-07-22 2026-01-01 Minovia Therapeutics Ltd Mitochondrial Augmentation Therapy for Primary Mitochondrial Diseases
EP3823645B1 (en) 2018-07-22 2024-07-03 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of renal diseases
US12440515B2 (en) 2018-07-22 2025-10-14 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of brain diseases
JP7458368B2 (ja) 2018-07-22 2024-03-29 ミノヴィア セラピューティクス リミテッド 筋疾患のミトコンドリア増強療法
US12239672B2 (en) 2018-07-22 2025-03-04 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of ocular diseases
EP3851112A4 (en) * 2018-09-14 2022-07-27 Luca Science Inc. TRANSPLANTATION OF MITOCHONDRIA INTO LYMPHORGAN AND COMPOSITION THEREOF
CN109796527B (zh) * 2019-03-07 2020-09-04 广西大学 一种红麻线粒体蛋白cox3抗原多肽及制备多克隆抗体的方法和应用
CN111034736B (zh) * 2019-12-13 2021-04-06 西北农林科技大学 一种杀虫组合物及其应用
CN111579763B (zh) * 2020-04-09 2023-04-07 北京博瑞世安科技有限公司 检测白细胞线粒体呼吸功能的方法及检测肾阴虚症的方法
CN111781175B (zh) * 2020-06-18 2023-04-21 中国人民解放军军事科学院国防科技创新研究院 一种用于提高细胞中线粒体活性的方法及装置和应用
WO2024015951A2 (en) * 2022-07-15 2024-01-18 Seq Biomarque, Llc Methods and materials for identifying biomarkers and/or pathways associated with alzheimer's disease
CN115960087B (zh) * 2022-09-16 2024-06-07 浙江工业大学 黏度响应型双光子荧光化合物及其合成与应用
CN117384269B (zh) * 2023-09-21 2024-06-18 南方医科大学南方医院 短肽mfrlp及其在制备动脉重塑相关疾病药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185244A (en) * 1989-12-08 1993-02-09 Emory University Genetic test for hereditary neuromuscular disease
US5296349A (en) * 1990-06-14 1994-03-22 Emory University Molecular genetic test for myoclonic epilepsy
US5494794A (en) * 1992-10-20 1996-02-27 Emory University Detection of mitochondrial DNA mutations associated with Alzheimer's disease and Parkinson's disease
US5506101A (en) * 1993-06-30 1996-04-09 Cedars-Sinai Medical Center Method for detection of susceptibility mutations for ototoxic deafness

Also Published As

Publication number Publication date
CN1150433A (zh) 1997-05-21
EP0751951A4 (en) 2000-05-03
NZ283660A (en) 1998-07-28
FI963884A0 (fi) 1996-09-27
EP0751951A1 (en) 1997-01-08
CA2186636A1 (en) 1995-10-12
FI963884A7 (fi) 1996-11-26
AU705230B2 (en) 1999-05-20
JPH09511398A (ja) 1997-11-18
AU2204295A (en) 1995-10-23
US20010021526A1 (en) 2001-09-13
BR9507241A (pt) 1997-09-16
NO964073D0 (no) 1996-09-27
MX9604400A (es) 1997-12-31
WO1995026973A1 (en) 1995-10-12

Similar Documents

Publication Publication Date Title
NO964073L (no) Diagnose og terapi samt cellulære og dyremodeller for sykdommer assosiert med mitokondriske defekter
Ortuño‐Lizarán et al. Phosphorylated α‐synuclein in the retina is a biomarker of Parkinson's disease pathology severity
Davis et al. Stress-induced activation of prefrontal cortex dopamine turnover: blockade by lesions of the amygdala
Perry et al. Decreased imipramine binding in the brains of patients with depressive illness
Kortekaas et al. Blood–brain barrier dysfunction in parkinsonian midbrain in vivo
Klivenyi et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Temlett et al. Increased iron in the substantia nigra compacta of the MPTP‐lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis
Wang et al. Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease
Forest et al. Protection against β‐amyloid neurotoxicity by a non‐toxic endogenous N‐terminal β‐amyloid fragment and its active hexapeptide core sequence
Caine Gilles de la Tourette's syndrome: a review of clinical and research studies and consideration of future directions for investigation
Zhang et al. Plasticity of dopamine D4 receptors in rat forebrain: temporal association with motor hyperactivity following neonatal 6-hydroxydopamine lesioning
NO20130115L (no) Farmasøytisk sammensetning omfattende et intestinalt kolesterolbindende protein.
Natori et al. THE 11,000-DALTON COMPONENT OF MOUSE II-2 ISOLATION AND IDENTIFCATION
McArdle et al. Accumulation of calcium by normal and dystrophin-deficient mouse muscle during contractile activity in vitro
WO2000066782A3 (en) Diagnostic assay for diabetes mellitus based on mutational burden
Wirtshafter et al. Chemogenetic inhibition of cells in the paramedian midbrain tegmentum increases locomotor activity in rats
Tseng et al. Immunohistochemical study of catecholamine enzymes and neuropeptide Y (NPY) in the rostral ventrolateral medulla and bulbospinal projection
Takahashi et al. Measurement of 5–Hydroxyindole Compounds During L‐5–HTP Treatment in Depressed Patients
Vuillemin et al. Pathogenesis of various forms of double outlet right ventricle in mouse fetal trisomy 13
Montpetit et al. Alteration of neuronal cytoskeletal organization in dorsal root ganglia associated with pyridoxine neurotoxicity
Asin et al. Amphetamine induces Fos-like immunoreactivity in the striatum of primates
Vos et al. Short and long term plasticity after lesioning of the cell body or terminal field area of the dopaminergic mesocorticolimbic system in the rat
Pena et al. Seropositivity in Dutch Crohn's disease patients against primed nude mouse lymph nodes, and the difference with lymphocytotoxic antibodies.
Friedrich et al. Autosomal deletions 46, XY, del (12)(p11) and 46, XY/46, XY, del (5)(p13) with no effect on physical or mental development
Byrom et al. The perceived cost of newer antipsychotics may be unfounded: predictions of a decision tree model

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application